Combining Immunotherapy with Transarterial Radioembolization

Genc Z. C. B., SOYDEMİR E., Ersoy S. A., ÖNEŞ T.

Indian Journal of Nuclear Medicine, cilt.38, sa.2, ss.145-147, 2023 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 38 Sayı: 2
  • Basım Tarihi: 2023
  • Doi Numarası: 10.4103/ijnm.ijnm_180_22
  • Dergi Adı: Indian Journal of Nuclear Medicine
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, EMBASE
  • Sayfa Sayıları: ss.145-147
  • Anahtar Kelimeler: Atezolizumab, fluorodeoxyglucose positron emission tomography-computed tomography, hepatocellular carcinoma transarterial radioembolization
  • Marmara Üniversitesi Adresli: Evet

Özet

Hepatocellular carcinoma (HCC) has a high mortality rate due to the diagnosis of patients at advanced stages and ineffective systemic therapies. Immunotherapy is considered a new treatment option for unresectable HCC alternatives to the limitations of conventional cytotoxic chemotherapy. In this case report, we reported that transarterial radioembolization and immunotherapy such as atezolizumab and bevacizumab can be used together in a manner effectively in the management of HCC treatment.